The initiative PATH for the vaccine against Malaria, MSD and the Langone of the University of New York Medical Center are collaborating in the investigation of a possible vaccine against the malaria
researchers try to block the activity of key proteins to prevent the malaria parasite in the liver
Bethesda, M.D., Whitehouse Station, N.J., New York, December of 2010. The development of a vaccine to prevent the malaria parasite is introduced in the human liver is the goal of a new partnership announced by world leaders in research and development of vaccines. The PATH initiative for vaccine against Malaria (MVI), MSD (known in the United States.)UU. (and Canada as Merck & Co) and the Centre medical Langone of the University of New York (NYU) collaborate to evaluate a strategy which takes a novel part of a major surface protein as diana in the malaria parasite. It is estimated that malaria is responsible for the deaths of nearly 900,000 people per year and that most of these relate to children under five in sub-Saharan Africa.
It was discovered that circumsporozoito (CSP) protein is a potential target in focus in the early stages of infection by malaria vaccine development. Researchers working in this project are focusing their efforts on a new strategy that has a region of the CSP that is important for a critical function of the protein as diana. It is expected that blocking this function, it can prevent liver invasion by the parasite, which is an essential phase that causes the disease of malaria.
Believe that we can improve the way in which vaccines are designed virosome strategically addressing this very important protein function ”, indicated the DRA. Elizabeth Nardin, Professor of the Department of medical parasitology in the NYU Langone Medical Center. Other approaches to get directed to the CSP vaccine have required extremely high antibody levels, and they are difficult to obtain and maintain. “This approach has the potential to remedy this problem.”
The justification for this targeted strategy of conjugate of peptides and proteins ” is based on the knowledge of the technology of vaccines to be used in the determination of a specific protein of malaria is known to cause an immune response. It has already shown that the CPS has an important protective efficacy in practice, in the context of the RTS, S vaccine most advanced candidate who is currently in a phase III clinical trial. In addition, MSD has included other vaccines based on conjugate that they have been developed against bacterial pathogens in pediatric vaccines approved and widely used.
History has shown that the vaccines can be a powerful tool against diseases, ” stated Dr. John Shiver, Vice President of discovery of vaccines of MSD. agree that the new methods and consortia, as this collaboration with MVI and the NYU Langone Medical Center, they are important to continue to innovate in the battle against the malaria parasite ”.
With the availability of a first generation malaria vaccine in perspective, we are increasing our efforts to find and fund scientific approaches for malaria vaccines that have the potential to be more efficient and protect more people ” explained Dr. Christian Loucq, director of MVI. we are very pleased that one of the largest pharmaceutical laboratories in the world and a Center medical academic have undertaken to test a promising new way to protect children from malaria ”.
Although this vaccine is being tested primarily for use in children under the age of one year, could be used to prevent disease in vulnerable to Plasmodium falciparum, the deadliest species of parasite, and potentially could be adapted to also prevent P. vivax. Approximately 40% of the world’s population living at risk of contracting malaria because of p. vivax or p. falciparum.
Though it is still quite early, we are delighted to have the opportunity to explore the promise of this innovative vaccine with MSD and MVI ”, noted Dr. Photini Sinnis, adjunct professor in medical parasitology in Center doctor Langone of the NYU.
On the PATH initiative for vaccine against Malaria (MVI)
The PATH initiative for the vaccine against Malaria (MVI) is a program on a global scale PATH established in 1999 with an initial grant from the Bill & Melinda Gates Foundation. MIV mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in developing countries. MVI vision is to achieve a world free of malaria.
On PATH
PATH is an international non-profit which creates solutions sustainable, culturally relevant, thus enabling communities worldwide to ending cycles of long-term ill-health. Through collaboration with various public and private sector institutions, PATH helps provide appropriate vital strategies that change the way in which people thinks and acts and health technology. The work of PATH improves the health and well-being around the world.
On the NYU Langone Medical Center
The Langone medical center of NYU , an academic medical center integrated global quality focused on patients, is one of the main centres of the United States.UU. for excellence in health care, biomedical research and medical education. Located in Midtown Manhattan, the NYU Langone Medical Center consists of three hospitals – Tisch Hospital, a tertiary facility in intensive care with 705 beds; the Institute of Medicine of rehabilitation Rusk, the first rehabilitation hospital in the world, with 174 beds and extensive programmes of rehabilitation for patients travelling, and the Hospital for diseases of the joints, there are 190 beds and it is one of the five hospitals in the world dedicated to the trauma and the Rheumatology – in addition to the Faculty of Medicine of the University of New York, one of the most prominent academic institutions of EE.U.S.
About MSD
now MSD is a leader in global health who works to contribute to global health. MSD is known as Merck in United States and Canada. Through our medicines, vaccines, biological therapies and consumption and veterinary products, we work with our clients operating in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increase access to health care through programmes of long range that they donate and deliver our products to the people who need it.
